45 Remarkably, the recent SELECT trial proved the cardiovascular efficacy of subcutaneous semaglutide in reducing the primary cardiovascular composite endpoint (death from cardiovascular causes, non-fatal MI or non-fatal stroke) in both overweight and obese patients with established atherosclerotic CVD
Contact your healthcare provider if cough develops shortly after starting tirzepatide and worsens with dose increases, because it may signal an individual sensitivity
Similarly, TZDs are as effective as GLP-1RAs in HbA 1C reduction, have fewer GI effects and may have a lower hypoglycaemia risk, but can cause weight gain
For L-carnitine, many trials use 1 to 3 grams per day and show modest improvements in body composition and exercise outcomes in some people, especially those with lower baseline levels
The beneficial effects of GLP-1 RAs on HRQoL and other outcomes in HFpEF are likely due to pleiotropic impacts, related or not to weight reduction, such as decongestion (mainly due to the reduction of increased plasma volume associated with obesity and epicardial constrain), reverse cardiac remodelling (mainly due to the decrease in epicardial fat and regression of left atrial and LV myopathy, lowering intracardiac pressure) and anti-inflammatory actions, among others